Here’s how COVID-19 vaccine guidance is changing in the U.S. For people at high risk of severe COVID-19. The process of reviewing and recommending yearly updates to the COVID-19

FDA COVID vaccine update is stirring major public attention as a new policy limits fall COVID-19 booster shots to seniors and high-risk individuals. While the FDA met to decide if vaccine formulas should change for fall 2025,

In a major policy shift, federal health officials anticipate the shots will be made available to adults 65 and older as well as children and younger adults who have one or more risk factors that make them more vulnerable to severe COVID-19.

Two global health groups that fund billions of dollars worth of critical medical aid - from childhood vaccines to malaria treatments - are in talks about merging some functions to help combat a financing crunch,

1️⃣ Grim warning: The world’s ice sheets are on course for runaway melting, leading to multiple feet of sea level rise and “catastrophic” migration. The dire prognosis from a group of international scientists suggests that coastlines will pay the heaviest price .

"Again, I don't want to give advice," Kennedy said. "I can tell you, in Europe, they don't use the chickenpox vaccine specifically because the preclinical trial shows that when you inoculate the population for chickenpox, you get shingles in older people, which is more dangerous."

The partners launched a phase 1a/1b trial of HB-400, an arenaviral therapeutic vaccine for chronic hepatitis B back in 2023, while the biotech’s early-stage trial of HB-500, an arenaviral therapeutic vaccine for HIV, is ongoing. Now, Gilead has decided ...